Patients with autoimmune disease often accumulate transient kidney stressors during pain treatment: NSAID exposure, ACE inhibitor or ARB therapy, diuretics, intermittent dehydration, and older age. I hypothesize that a time-updated model using short-interval creatinine slope plus explicit triple-whammy exposure (NSAID + ACEi/ARB + diuretic) will predict clinically meaningful NSAID-associated AKI better than baseline eGFR alone.

Why this is plausible

• Baseline CKD increases susceptibility, but AKI risk is strongly context-dependent rather than static.
• The classic 'triple-whammy' combination has already shown measurable AKI excess in population data.
• A slope-based signal should detect evolving renal hemodynamic injury earlier than a single baseline measure.

Testable design

• Prospective multicenter cohort of adults with autoimmune or inflammatory musculoskeletal disease who start or intensify NSAID therapy.
• Collect baseline eGFR, albuminuria, age, diabetes, ACEi/ARB use, diuretic use, heart failure/cirrhosis, hydration or sepsis flags, and repeat creatinine within 3-7 days and 10-14 days.
• Primary endpoint: KDIGO-defined AKI within 14 days.
• Compare discrimination and calibration of:
  1. baseline eGFR alone
  2. baseline multivariable model
  3. time-updated creatinine-slope + exposure-context model
• Prespecified metrics: AUROC, calibration slope, decision-curve analysis, and net reclassification improvement.

Falsifiable predictions

1. The time-updated model will improve AUROC by at least 0.07 over baseline eGFR alone.
2. The largest gain will occur in patients exposed to the NSAID + ACEi/ARB + diuretic combination.
3. Calibration drift will be smaller when creatinine slope is included than when static baseline variables are used alone.

Key limitations

• Confounding by indication and intercurrent illness must be addressed.
• Creatinine slope can reflect non-NSAID causes of AKI.
• External validation is required before bedside deployment.

References

1. Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S, Hennessy S. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ. 2013;346:e8525. DOI: 10.1136/bmj.e8525
2. Dreischulte T, Morales DR, Bell S, Guthrie B. Combined use of nonsteroidal anti-inflammatory drugs with diuretics and renin-angiotensin system inhibitors in the community increases the risk of acute kidney injury. Kidney Int. 2015;88(2):396-403. DOI: 10.1038/ki.2015.101
3. Kellum JA, Lameire N. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary. Crit Care. 2013;17(1):204. DOI: 10.1186/cc11454